FR05C0022I2 - - Google Patents

Info

Publication number
FR05C0022I2
FR05C0022I2 FR05C0022C FR05C0022C FR05C0022I2 FR 05C0022 I2 FR05C0022 I2 FR 05C0022I2 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I2 FR05C0022 I2 FR 05C0022I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0022C
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (fr) 1995-03-30 1996-03-28 Combinaisons synergiques de zidovudine, 1592u89 et 3tc ou ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 FR05C0022I1 (fr) 2005-06-10
FR05C0022I2 true FR05C0022I2 (fr) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (fr) 1995-03-30 2005-05-09

Country Status (36)

Country Link
US (1) US6417191B1 (fr)
EP (1) EP0817637B1 (fr)
JP (1) JP2954357B2 (fr)
KR (1) KR100542536B1 (fr)
CN (1) CN1103593C (fr)
AP (1) AP652A (fr)
AT (1) ATE220551T1 (fr)
AU (1) AU715213B2 (fr)
BR (3) BR9607851B1 (fr)
CA (1) CA2216634C (fr)
CZ (1) CZ295940B6 (fr)
DE (3) DE122005000029I1 (fr)
DK (1) DK0817637T3 (fr)
EA (1) EA000626B3 (fr)
EE (1) EE04047B1 (fr)
ES (1) ES2179193T3 (fr)
FR (1) FR05C0022I2 (fr)
GE (1) GEP20022647B (fr)
HK (1) HK1009401A1 (fr)
HU (1) HU224010B1 (fr)
IL (1) IL117727A (fr)
LU (1) LU91171I2 (fr)
MX (1) MX9707316A (fr)
MY (1) MY115461A (fr)
NL (1) NL300195I2 (fr)
NO (2) NO313787B1 (fr)
NZ (1) NZ306419A (fr)
OA (1) OA10616A (fr)
PL (1) PL187085B1 (fr)
PT (1) PT817637E (fr)
RO (1) RO117995B1 (fr)
SI (1) SI0817637T1 (fr)
SK (1) SK283825B6 (fr)
TR (1) TR199701074T1 (fr)
UA (1) UA60293C2 (fr)
WO (1) WO1996030025A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9903249A3 (en) * 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
EP0979082A1 (fr) * 1997-05-17 2000-02-16 Glaxo Group Limited Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
WO1999060988A2 (fr) * 1998-05-29 1999-12-02 University Of Florida Therapie combinee pour le traitement des infections dues au vif
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2004085406A1 (fr) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinones en tant qu'inhibiteurs de transcriptase inverse
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007045573A1 (fr) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phénylacétamides en tant qu'inhibiteurs de nnrt
WO2008071587A2 (fr) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Inhibiteurs non nucléosidiques de la transcriptase inverse
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
AU2010251880B2 (en) 2009-05-27 2015-07-30 Biotempus Pty Ltd Methods of treating diseases
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
WO2015028875A2 (fr) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir et un comprimé monolithique comprenant du darunavir et du ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱(Emtricitabine)、替諾福韋(Tenofovir)、地瑞那韋(Darunavir)及利托那韋(Ritonavir)之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019046491A1 (fr) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. Promédicaments lipidiques orientant vers le système lymphatique
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
CA3166908A1 (fr) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Promedicaments lipidiques de neurosteroides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
AU1787492A (en) * 1991-05-16 1992-12-30 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
CZ429398A3 (cs) 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
CZ309097A3 (cs) 1998-05-13
BRPI9612992B1 (pt) 2020-08-04
IL117727A0 (en) 1996-07-23
EP0817637B1 (fr) 2002-07-17
BR9607851A (pt) 1998-07-21
PL187085B1 (pl) 2004-05-31
DE69622386T2 (de) 2003-02-13
NL300195I1 (nl) 2005-08-01
DE122005000029I2 (de) 2006-04-27
ATE220551T1 (de) 2002-08-15
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
NL300195I2 (nl) 2005-11-01
US6417191B1 (en) 2002-07-09
EP0817637A1 (fr) 1998-01-14
TR199701074T1 (xx) 1998-02-21
CN1185110A (zh) 1998-06-17
BR9607851B1 (pt) 2009-01-13
KR19980703420A (ko) 1998-11-05
AU5497296A (en) 1996-10-16
UA60293C2 (uk) 2003-10-15
RO117995B1 (ro) 2002-12-30
CN1103593C (zh) 2003-03-26
WO1996030025A1 (fr) 1996-10-03
JP2954357B2 (ja) 1999-09-27
NO974510L (no) 1997-09-29
LU91171I2 (fr) 2005-07-04
SK129597A3 (en) 1998-07-08
HU224010B1 (hu) 2005-04-28
CA2216634A1 (fr) 1996-10-03
NO974510D0 (no) 1997-09-29
ES2179193T3 (es) 2003-01-16
FR05C0022I1 (fr) 2005-06-10
EA199700203A1 (ru) 1998-02-26
PL322532A1 (en) 1998-02-02
CA2216634C (fr) 2004-07-20
EA000626B1 (ru) 1999-12-29
BRPI9607851B8 (pt) 2019-11-05
NO313787B1 (no) 2002-12-02
AP652A (en) 1998-06-19
SK283825B6 (sk) 2004-02-03
EA000626B3 (ru) 2016-04-29
OA10616A (en) 2001-03-15
EE04047B1 (et) 2003-06-16
MY115461A (en) 2003-06-30
CZ295940B6 (cs) 2005-12-14
EE9700240A (et) 1998-04-15
HUP9801571A3 (en) 2001-04-28
KR100542536B1 (ko) 2006-03-23
DK0817637T3 (da) 2002-11-11
LU91171I9 (fr) 2018-12-28
IL117727A (en) 1999-11-30
NO2005014I1 (no) 2005-06-06
DE122005000029I1 (de) 2005-10-06
MX9707316A (es) 1997-11-29
SI0817637T1 (en) 2002-10-31
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
JPH10511682A (ja) 1998-11-10
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
AU715213B2 (en) 2000-01-20
HK1009401A1 (en) 1999-09-10
NO2005014I2 (no) 2008-02-11

Similar Documents

Publication Publication Date Title
DE69638352D1 (fr)
DE69637714D1 (fr)
FR05C0022I2 (fr)
BR122012014331A2 (fr)
BRPI9612258B1 (fr)
BRPI9612138B1 (fr)
CH0741373H1 (fr)
DK0727898T3 (fr)
IN183362B (fr)
BR7502120U (fr)
IN185793B (fr)
IN187218B (fr)
IN188139B (fr)
BR7501503U (fr)
AU1627395A (fr)
IN184955B (fr)
CN3033635S (fr)
CN3035869S (fr)
CN3032390S (fr)
CN3032568S (fr)
CN3032692S (fr)
CN3033225S (fr)
CN3031742S (fr)
CN3033771S (fr)
CN3034473S (fr)